Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040014/S052

Therapy (including Bi-Directional and 4mm Thermistor) Ablation Catheter

Irvine Biomedical, Inc. · Decision date Sep 3, 2026

MEDTECHLEDGER EXPLANATIONP040014/S052

What did the FDA decide?

FDA recorded a 30-Day Notice decision coded OK30 on 2026-09-03 for P040014/S052, a supplement to the Therapy (including Bi-Directional and 4mm Thermistor) Ablation Catheter, a cardiac ablation percutaneous catheter in the cardiovascular specialty under product code LPB. The applicant is Irvine Biomedical, Inc.

The recorded scope is a manufacturing process change: adding an alternate epoxy in the manufacture of the temperature sensor. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. This entry documents that specific change to the device's sensor manufacturing rather than a new approval of the whole catheter system. The source record includes no documents, so the epoxy's identity, supplier qualification data and any testing supporting the change are not available here.

The decision code OK30 is not expanded in the source, and its precise meaning is left unstated. No clinical, performance or labeling conclusions follow from this record.

FDA approval order statement

to add an alternate epoxy in the manufacture of the temperature sensor
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 3, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P040014/S052
Regulatory pathway
PMA supplement
Product code
LPB
Decision code
OK30
Decision date
Sep 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cardiac ablation percutaneous catheter.

Product code
LPB
FDA device class
3

For the original device and its historical approval scope, see PMA P040014. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P040014 · Original PMA

    IBI THERAPY CARDIAC ABLATION SYSTEM ERS/ 1500T RF GENERATOR

  2. P040014/S052 received

    Application receipt date recorded by FDA.

  3. P040014/S052 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P040014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040014

Product / regulatory recordCompanyPathwayDecision dateSource
Irvine Biomedical, Inc.PMA approvalJan 14, 2005FDA

Explore the linked device profile

Other records with product code LPB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Irvine Biomedical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2375 Morse Ave., Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records